SETD1A Pharmaceutical composition for preventing or treating anticancer drug resistant breast cancers comprising expression or activity inhibitor of SETD1A as an active ingredient

摘要

The present invention relates to a pharmaceutical composition for preventing or treating anticancer drug resistant breast cancer, the pharmaceutical composition containing an expression or activity inhibitor of SETD1A as an active ingredient. Specifically, it is confirmed that SETD1A is over-expressed in a breast cancer cell compared to a normal breast cell. When a specific gene expression, which is induced to an estrogen receptor in a breast cancer cell, is adjusted, and an expression of SETD1A is made to decrease in a cell, it is confirmed that proliferation of breast cancer cell lines is suppressed, that apoptosis is significantly induced, and that a cell migration is reduced. When tamoxifen is treated onto a cell and an expression of SERD1A is made to decrease, it is confirmed that cancer cell proliferation suppressing, apoptosis inducing, and cell migration suppressing effects are improved compared to when only tamoxifen is treated. Also, when an expression of SETD1A is suppressed in a breast cell which has resistance to tamoxifen, it is confirmed that proliferation of cells is significantly reduced. Accordingly, the composition, containing an expression or activity inhibitor of SETD1A as an active ingredient, of the present invention can be useful for treatment of anticancer drug resistant breast cancer.